Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- ...
BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...
Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb.
Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective February 14, 2025, Amit Munshi, a member of the Board of Directors of the Company (the “Board”) and veteran ...
Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes.